A paradigm shift in the era of omics, AI, and personalized medicine

• Javad Nazarian – BrainStorm Summit

  Translational scientist, trying to find a cure for patients diagnosed with DIPG / DMG. Dr. Javad Nazarian is the Scientific Director of the Brain Tumor Institute at Children’s National Hospital in Washington, D.C. and the Head of DMG Research Center at University Children’s Hospital in Zurich, Switzerland. He is also an Associate Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences in Washington, D.C. In his role, Dr. Nazarian has formed national and international collaborations to establish a translational and multi-disciplinary team focusing on childhood high grade gliomas.

• A paradigm shift in the era of omics, AI,and personalized medicine

  Javad Nazarian, PhD Professor, University of Zurich, Department of Pediatrics Head, DMG/DIPG Research Center, University Children’s Hospital Zurich Scientific Co-Chair, Children’s Brain Tumor Network Adjunct Associate Professor of Pediatrics, George Washington University

Advances in Effective Drug Delivery

• Joelle Straehla

• Adam Green – BrainStorm Summit

  Adam Green, MD, is an Associate Professor of Pediatrics at the University of Colorado School of Medicine and an attending pediatric neuro-oncologist at Children’s Hospital Colorado. He completed his undergraduate degree in neurobiology at Dartmouth College and attended medical school at NYU. He served as a resident and chief resident in pediatrics at the University of Colorado and as a pediatric hematology-oncology fellow at Dana-Farber Cancer Institute and Boston Children’s Hospital. There, he trained in translational research in pediatric brain tumors with Drs. Andrew Kung and Stu Orkin, and in childhood cancer disparities with Dr. Carlos Rodriguez Galindo.

• Cheng-Chia Wu – BrainStorm Summit

  I am a physician scientist with dual M.D./Ph.D. degrees and is currently a Tenure-Track Assistant Professor at Fralin Biomedical Research Institute (FBRI) at Virginia Tech Carilion (VTC) with academic appointments in the Department of Internal Medicine, at Virginia Tech School of Medicine (VTSOM) and Biomedical Engineering and Mechanics (BEAM). My clinical focus is on pediatric cancers, central nervous system (CNS) cancers, and sarcomas. I am the executive lead for the Advanced Technology and Drug Delivery Initiative (ADTI) laboratories dedicated to pediatric brain tumors.

• Advances in Effective Drug Delivery

Advocacy – CAC2

by Coalition Against Childhood Cancer (CAC2) presented in Chinese Ballroom by: Ann Ramer Bobbi Krabill Aubrey Reichard-Eline Leia Hunt

• Using Your Story to Advocate: State and Local Opportunities

• Advocacy – Your Unique Story

  by Coalition Against Childhood Cancer (CAC2)

AI/ML Discovery & Experimental Validation of Novel Predictors

• Orly Alter – BrainStorm Summit

  Orly Alter is a USTAR associate professor of bioengineering and human genetics at the Scientific Computing and Imaging Institute and the Huntsman Cancer Institute at the University of Utah, a scientific advisory board member of the NCI-DOE Cancer Moonshot collaboration on predictive oncology, and the CSO and a co-founder of Prism AI Therapeutics, Inc. Alter received her Ph.D. in applied physics at Stanford University and her B.Sc. magna cum laude in physics at Tel Aviv University. Her Ph.D. thesis, which was published by Wiley, is recognized as crucial to gravitational wave detection and quantum computing.

• AI/ML Discovery & Experimental Validation of Novel Predictors

  Orly Alter USTAR Associate Professor of Bioengineering & Human Genetics, Scientific Computing & Imaging Institute & Huntsman Cancer Institute, University of Utah, & CSO & Co-Founder, Prism AI Therapeutics, Inc.

Biological Therapies for Pediatric Brain Tumors: Virus and more!

• Biological Therapies for Pediatric Brain Tumors: Virus and more!

  Clínica Universidad de Navarra, Pamplona, Spain. Centro de Investigación Médica Aplicada, Pamplona, Spain

Cancer Commons: Learning Health System

• Cancer Commons - Help for those with advanced cancer

  Cancer Commons is a nonprofit that gives compassionate support for people with advanced or metastatic cancer. Click if you need help with diagnostic tests or treatment options

• Cancer Commons: Learning Health System

  Developed in Collaboration with the Musella Foundation For Brain Tumor Research & Information

CAR T Cell Therapy: From Bench to Bedside

• Jessica Foster – BrainStorm Summit

  Dr. Foster is an Assistant Professor in the Division of Oncology, Department of Pediatrics, at the Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania. Her research and clinical interests lie in bringing immunotherapy to use in pediatric central nervous system tumors. Specifically she is studying chimeric antigen receptor (CAR) T cells and translating them to the clinic. Our Third Annual Event! New Location Thursday September 19th – Saturday September 21st

• CAR T Cell Therapy: From Bench to Bedside

  Moderator: Jessica Foster, MD

CAR T Cells: Full Circle – From Bedside to Bench and Back Again

• Dalia Haydar

  Dalia Haydar, Pharm.D., Ph.D., is an Assistant Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences and a leading Research Faculty member at the Center for Cancer and Immunology Research at Children’s National Hospital. Renowned for her pioneering work in CAR T cell immunotherapy for pediatric brain tumors, Dr. Haydar is dedicated to overcoming the challenges posed by host factors that limit responses to adoptive immunotherapies. Through groundbreaking mechanistic investigations and the application of advanced technologies, she is driving the development of next-generation cellular immunotherapies, poised to significantly enhance outcomes for children battling brain tumors.

• CAR T Cells: Full Circle – From Bedside to Bench and Back Again

  Translating Clinical Insights into Preclinical Innovations Dalia Haydar, PharmD, PhD Research Faculty Center for Cancer and Immunology Research, Children’s National Research Institute Assistant Professor of Pediatrics The George Washington University, School of Medicine and Health Sciences

CAR T-cell therapy trials

• Michelle Monje – BrainStorm Summit

  Michelle Monje, MD, PhD, is a Professor of Neurology at Stanford University and a Howard Hughes Medical Institute Investigator. She received her M.D. and Ph.D. in Neuroscience from Stanford and completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School Partners program, and then returned to Stanford for a clinical fellowship in pediatric neuro-oncology. Her research program focuses at the intersection of neuroscience, immunology and brain cancer biology with an emphasis on neuron-glial interactions in health and oncological disease. Her laboratory studies how neuronal activity regulates healthy glial precursor cell proliferation, new oligodendrocyte generation, and adaptive myelination; this plasticity of myelin contributes to healthy cognitive function, while disruption of myelin plasticity contributes to cognitive impairment in disease states like cancer therapy-related cognitive impairment.

• CAR T-cell therapy trials

  Michelle Monje, MD, PhD Milan Gambhir Professor of Pediatric Neuro-Oncology Chambers-Okamura Director for Pediatric Neuro-Immuno-Oncology Investigator, Howard Hughes Medical Institute Department of Neurology and Neurological Sciences Stanford University

ChadTough

• ChadTough

Challenges of Survivorship

• Neuro-Oncologist Joins UCSF Brain Tumor Center Team | UCSF Brain Tumor Center

  This month, neuro-oncologist Jessica Schulte, MD, PhD joins the UCSF Brain Tumor Center team. Dr. Schulte specializes in treatment of adolescent and adult glioma and neurofibromatosis.

• Challenges of Survivorship

  Jessica Schulte, MD, PhD Assistant Professor of Neurosciences Neuro-oncology and Neurofibromatosis Program Moores Cancer Center University of California, San Diego

Chimerix

• ONC201 (dordaviprone) in H3 K27M mutant glioma

• Dordaviprone (ONC201): H3 K27M-Mutant Diffuse Midline Glioma Program and ACTION Study

  Nicholas E. Wojtynek, PhD Senior Director, Field-Based Medical Affairs

Clinical experiences with CAR T cell therapy for DIPG and spinal cord DMG

• Michelle Monje – BrainStorm Summit

  Michelle Monje, MD, PhD, is a Professor of Neurology at Stanford University and a Howard Hughes Medical Institute Investigator. She received her M.D. and Ph.D. in Neuroscience from Stanford and completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School Partners program, and then returned to Stanford for a clinical fellowship in pediatric neuro-oncology. Her research program focuses at the intersection of neuroscience, immunology and brain cancer biology with an emphasis on neuron-glial interactions in health and oncological disease. Her laboratory studies how neuronal activity regulates healthy glial precursor cell proliferation, new oligodendrocyte generation, and adaptive myelination; this plasticity of myelin contributes to healthy cognitive function, while disruption of myelin plasticity contributes to cognitive impairment in disease states like cancer therapy-related cognitive impairment.

• Clinical experiences with CAR T cell therapy for DIPG and spinal cord DMG

  Michelle Monje MD, PhD Neuro-Immuno-Oncology Program Center for Cancer Cellular Therapy Department of Neurology and Neurological Sciences Howard Hughes Medical Institute Stanford University

CONNECT: TarGeT

• Eugene Hwang, MD – BrainStorm Summit

  Dr. Gene Hwang is a pediatric neuro-oncologist at Children’s National Hospital in Washington, DC, where he also serves as the Chief of Oncology and holds the William Hughes Professorship in Neuro-oncology and Immunology. He also the Vice Chair of the Brain Tumor Institute, the Director of Clinical Neuro-immunotherapy, and is the Chair of several working groups involving immunotherapy and specific pediatric CNS tumors in various consortia. Dr. Hwang’s focus is on early phase clinical trials, leading or co-leading 8 current trials in this space, and participating in multiple think-tanks aimed at improving treatment options for children with brain cancer.

• CONNECT: TarGeT

  Eugene Hwang, MD Children’s National Hospital

Creating Space to Honor and Remember

• Creating Space to Honor and Remember

DDRFA

• DDRFA

Developing diagnostic tests to help improve survival for brain cancer patients

• Amanda Paulovich – BrainStorm Summit

  “Amanda Paulovich, M.D., Ph.D.Professor and Aven Foundation Endowed ChairDirector, CLIA Targeted Proteomic LaboratoryTranslational Science and Therapeutics DivisionFred Hutchinson Cancer Center Professor, Department of Medicine / Division of Hematology & OncologyUniversity of Washington School of Medicine Dr. Paulovich is Professor and Aven Foundation Endowed Chair at the Fred Hutchinson Cancer Center and Professor at the University of Washington School of Medicinein Seattle. As a medical oncologist, Dr. Paulovich was struck by the paucity of effective diagnostics for measuring clinically relevant phenotypes in her patients, and the limitations that this put on her ability to practice “personalized oncology.” One patient’s tumor would melt away with standard of care therapy, whereas another patient with what appeared to be the same tumor would nonetheless experience disease progression on the same therapy. One patient would experience life-threatening toxicity, whereas another patient receiving the same therapy would not develop side effects.

• Developing diagnostic tests to help improve survival for brain cancer patients

  Amanda G. Paulovich, M.D., Ph.D. • Professor and Aven Foundation Endowed Chair, Fred Hutchinson Cancer Center, Seattle WA • Director, Clinical Research Proteomics Platform, Brotman Baty Institute for Precision Medicine • Professor, Division of Oncology, University of Washington School of Medicine

Discovering next-generation epigenetic drugs for disease

• Laura Hsieh – BrainStorm Summit

  Dr. Laura Hsieh, co-founder and CEO of TippingPoint Biosciences, is a former UCSF postdoc in Geeta Narlikar’s lab. Dr. Hsieh obtained her Ph.D from University of Washington/Fred Hutchinson Cancer Research Center in Cellular and Molecular Biology. She has authored multiple first author publications and is the recipient of an American Cancer Society postdoctoral fellowship. During the course of her career, Dr. Hsieh has directed several team projects, invented and built TippingPoint Bio’s core technology platform at UCSF, was accepted into many competitive accelerator and mentorship programs, won multiple pitch competitions sponsored by Pharma, and successfully closed on $1.5M pre-seed financing to spin TippingPoint Bio out of UCSF.

• Discovering next-generation epigenetic drugs for disease

  Laura Hsieh TIPPINGPOINT BIOSCIENCES

Exploring the role for dietary intervention in brain tumors

• Sameer Agnihotri – BrainStorm Summit

  Associate Professor, Department of Neurological Surgery. Children’s Hospital, University of Pittsburgh. Our Third Annual Event! New Location Thursday September 19th – Saturday September 21st This summit will bring experts in the field of pediatric neuro-oncology and many opportunities for anyone wanting to learn more about the #1 disease-related killer of our children: Brain Cancer! Lisa Ward, Summit Coordinator Tough2gether Against DIPG 1600 Poyntz Ave. Manahttan, KS 66502 info.tough2gether@gmail.com © 2024 BrainStorm Summit - WordPress Theme by Kadence WP

• Exploring the role for dietary intervention in brain tumors

  Sameer Agnihotri, PhD Dept Neurological Surgery Children’s Hospital, University of Pittsburgh

Foundations of CSF circulating tumor DNA liquid biopsy in CNS tumors

• Alexandra M. Miller, MD | NYU Langone Health

  Meet doctor Alexandra M. Miller, MD, Neuro-Oncologist, and learn about conditions treated, training, and research at NYU Langone. Read more.

• Foundations of CSF circulating tumor DNA liquid biopsy in CNS tumors

  Alexandra Miller Director of Neuro-oncology Co-director of the Brain and Spine Tumor Center Perlmutter Cancer Center NYU Langone Health

Giving Grief Room

• Giving Grief Room

Immunotherapy Going Viral

• Gregory Friedman – BrainStorm Summit

  Gregory Friedman, MD, specializes in pediatric neuro-oncology and conducting pediatric brain tumor translational and clinical research as Professor of Pediatrics and Section-Chief of Pediatric Neuro-Oncology at the University Texas MD Anderson Cancer Center. He previously served as Director of Developmental Therapeutics for the Alabama Center for Childhood Cancer & Blood Disorders at the University of Alabama at Birmingham and as the site PI for the Children’s Oncology Group (COG) Pediatric Early Phase-Clinical Trial Network (PEP-CTN). His overarching goal is to improve outcomes for children with brain tumors by developing and improving novel, targeted immunotherapies in the lab and then translating these therapies to clinical trials. His research is focused on determining mechanisms of cancer cell therapeutic resistance to novel therapies by exploring the role of the tumor microenvironment and cellular defense mechanisms to circumvent resistance mechanisms. His experience in managing pediatric neuro-oncology patients and in conducting clinical oncology research complements his laboratory experience, which has enabled his team to develop a greater understanding of the tumor microenvironment and translate innovative immunotherapies from bench-to-bedside. He was the Principal Investigator (PI) for the first completed oncolytic virotherapy (G207) pediatric brain tumor trial (NCT02457845; published in New England Journal of Medicine in 2021), and he is the PI for an ongoing first-in-human trial of G207 in recurrent cerebellar tumors (NCT03911388). In addition, he developed and leads a Phase 2 trial of G207 through the NCI-supported Pediatric Brain Tumor Consortium in recurrent pediatric high-grade glioma. His research has been supported by the National Institutes of Health and the U.S. Food and Drug Administration, the Department of Defense, and numerous pediatric cancer foundations

• Immunotherapy Going Viral:Advances in Oncolytic Virotherapy for Pediatric Brain Tumors

  Gregory Friedman, M.D. Professor, Pediatrics Section Chief, Pediatric Neuro-Oncology

Insights from Multi-modal data

• Sarah Brueningk – BrainStorm Summit

  Sarah is a physicist by training (TU Munich, Germany) and completed a PhD at the intersection of practical wet lab and computational biology at the Institute of Cancer Research (UK). Today, she is a group leader for pediatric oncology applications within the Biomedical Data Science lab at ETH Zurich. Her research harnesses combinations of mathematical modelling and advanced machine learning to optimize therapy for pediatric brain tumors from multimodal data. As part of this project, she closely collaborate with the Pacific Pediatric Neuro-Oncology Consortium and the DMG Center Zurich.

• Insights from Multi-modal data

  Sarah Brüningk, PhD Group Leader Pediatric Oncology ApplicationsBiomedical Data Science Lab, ETH Zurich Professor of AI University of Applied Science Northwestern Switzerland

Interviews with childhood cancer warriors & their families

• Interviews with childhood cancer warriors & their families

KIDSvCANCER.ORG

• RI-D1-Nancy